China NMPA approves Keymed Biosciences’ Stapokibart for atopic dermatitis
The National Medical Products Administration (NMPA) of China has approved Keymed Biosciences’ new drug application granting marketing approval for Stapokibart to treat adults with moderate-to-severe atopic dermatitis.